Population‑scale genetic testing for drug‑response variants could be justified: nearly every person carries at least one variant linked to altered drug dosing or choice, and about one quarter had been prescribed a drug affected by their genotype in this All of Us sample. Implementing routine pharmacogenomic screening would require outcome trials, clinician decision support, equity‑focused databases, and changes to reimbursement and prescribing workflows.
— Adopting routine pharmacogenomic screening would reshape clinical practice, drug formularies, insurance coverage, and could reduce adverse reactions and unequal care across ancestry groups.
Philip Empey
2026.11.22
100% relevant
All of Us analysis of ~100,000 whole genomes: 99.5% carried variant with FDA/guideline actionability; ~24% had taken an affected drug; 17,704 previously unreported coding variants identified.
← Back to all ideas